

Oncogenic drivers in NSCLC
September 1st, 2022



GAS/ECR/ICR

nicht frankieren
ne pas affranchir
non affrancare

50952904
000001

SWISS POST

A



med•today

medtoday Switzerland

c/o PlayToKnow AG

Alte Landstrasse 55

8802 Kilchberg

Join today. Shape tomorrow.

Register free of charge on [medtoday.ch](https://www.medtoday.ch)
and become part of a unique professional community!

Organizer

medtoday Switzerland | c/o PlayToKnow AG

Alte Landstrasse 55, 8802 Kilchberg

Sybille Holtkamp | +41 78 708 09 46 | info@medtoday.ch

The event is financially supported by

Lead Sponsor



Thurgauerstrasse 130
8152 Glattpark-Opfikon

Co-Sponsor

AMGEN®

med
today

Oncogenic drivers
in NSCLC

September 1st, 2022

Treating mutations ALK+, EGFR exon
20 ins+, KRAS in NSCLC: Which are
the therapeutic paradigms today?

www.medtoday.ch

Webinar

Credits
SGAIM,
SGR, SGMO,
SGPath
requested

Dear colleagues

I am pleased to invite you to the webinar „Oncogenic drivers in NSCLC“ on Thursday, September 1st, 2022. In the first part of the webinar, a pathologist will explain the best testing approaches for identifying the oncogenic mutations today. Then, our high-profile experts will discuss the current treatment options for specific mutations. In the third and discussion part, the faculty of experts appreciate your active participation in the form of Q&A.

We look forward to seeing you virtually and having exciting exchanges.

Many greetings
Prof Solange Peters



Oncogenic Drivers in NSCLC

September 1st, 2022

17:30 – 19:30 Uhr




Webinar

The participation is free of charge. The event language is English. Please register using the enclosed reply card, via our website www.medtoday.ch or QR code below.

medtoday.ch/med-ed/mutations-nslc-2022

info@medtoday.ch



Program

17:30 – 17:35

Introduction

Prof Solange Peters

17:35 – 17:55

Part 1 – Oncogenic drivers detection: State of the art in today's pathology

Prof Lukas Bubendorf

17:55 – 18:20

Part 2 – Treatments of ALK+ NSCLC: Therapy Considerations and Selection

Dr Alfredo Addeo

18:20 – 18:45

Part 3 – Targeting EGFR exon 20 insertion mutated NSCLC

Prof Alexis Cortot

18:45 – 19:10

Part 4 – Current treatment options for KRAS mutated NSCLC

PD Dr Alessandra Curioni

19:10 – 19:30

Part 5 – Discussion with Q&A

Chair



Prof Solange Peters

Lausanne University Hospital
CHUV, Switzerland

Speakers



Dr Alfredo Addeo

University Hospital Geneva
HUG-Geneva University Hospitals



Prof Lukas Bubendorf

University Hospital Basel
USB, Switzerland



Prof Alexis Cortot

University Hospital Lille
CHRU, France



PD Dr Alessandra Curioni

University Hospital Zurich
USZ, Switzerland

Registration



Webinar

Title

First name

Last name

Institution

Oncogenic drivers in NSCLC

September 1st, 2022

Street and number

Post code and city

E-Mail

Phone